Business Wire

AZ-WORLD-VIEW

17.3.2022 15:46:04 CET | Business Wire | Press release

Share
World View Introduces Space Capsule Prototype Carrying Passengers to the Edge of Space

World View , an expert in stratospheric exploration on a mission to help spaceflight participants rediscover Earth, today announces the debut of its spaceflight capsule prototype. The announcement marks another exciting milestone for the company, following recent news of its entry into the space tourism sector and appointment of President of Tourism and Exploration, Dale Hipsh.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005669/en/

Spaceflight participants eagerly awaiting the launch of commercial flights beginning in 2024 are provided a first-look at the distinctive World View experience, from onboard amenities and design touches to the superior hospitality and life-changing perspectives enjoyed throughout the journey.

“Unveiling our space capsule prototype is a pivotal moment for the company as we continue to prepare for our first launch from the Grand Canyon in just two short years,” said Ryan Hartman, President and Chief Executive Officer of World View. “We are thrilled to partner with leaders in aerospace design and engineering to bring our vision to life and ensure spaceflight participants enjoy a truly transformative experience.”

The exterior of the World View space capsule is shaped like a faceted hexagon with softened edges and a pearlescent white finish, which offers thermal management properties but also enhances the geometric detailing and curves. It boasts large elliptical windows that measure approximately 6.5 feet wide x 4.5 feet high, framing impressive views of the Earth’s curvature and its natural wonders. When seats are in a reclined position, the sky window on top of the capsule provides passengers an exciting line of sight to the balloon lifting them as well as constellations upon reaching float altitude. The central ceiling pelmet also includes a mood wash light that changes in accordance with the stage in flight to provide optimal viewing out of the capsule’s windows.

The capsule is climate-controlled and pressurized with an entire interior designed to maximize space, allowing spaceflight participants to move freely and comfortably about the capsule. The color palette, materials and finishes create an environment of calm, with clean lines, soft tones and clever concealment of functional elements–such as lavatory and galley entrances–so the focus remains on the stunning vistas and sights outside. Aligned with World View’s commitment to sustainability, great care is being taken to ensure materials are sourced from sustainable vendors whenever possible and options for re-use or recycling are being thoroughly explored.

Luxurious, ergonomic seating for eight passengers is configured in pairs, with an additional pair designated for crew members. Amenities including a cocktail table, graphical user interface (GUI) screen (providing educational materials and engaging activities), central console, personal storage and beverage holder, are at spaceflight participants’ fingertips to ensure that no moment of the journey is missed. Each capsule is outfitted with an onboard telescope to maximize viewing throughout the journey. Spaceflight participants will also enjoy gourmet custom dining options and top-shelf libations throughout their flight and each capsule will be equipped with streaming and mobile communication capabilities to stay in touch with loved ones back on Earth.

Projected lift off is scheduled before dawn, providing participants a front row seat to the sunrise on most flights. Along the journey, passengers will take in the curvature of the Earth, thin blue line of the atmosphere, vast darkness of space and constellations. Without the typical turbulence found on an airplane flight, spaceflight participants will be able to stand and move about the craft shortly after launch. The onboard crew, including one pilot and one concierge, serve as both Earth and space guides, cross-trained in flight operations, hospitality and medical support.

World View’s space tourism program begins launching commercial flights in 2024 with voyages taking off from natural and man-made wonders such as the Grand Canyon and Great Barrier Reef. Flights will lift passengers in a zero-pressure stratospheric balloon and pressurized space capsule to 100,000 feet altitude, nearly 23 miles above Earth, for an unparalleled experience that will last six to eight hours. Participants will fully experience and immerse themselves in the beauty, fragility, history and importance of the areas surrounding each location and of the Earth itself.

Design elements and engineering considerations continue to be refined. Further information on World View available at worldview.space .

ABOUT WORLD VIEW

World View is the leading stratospheric exploration company on a mission to inspire the global community to rediscover Earth. Through both its legacy Stratollite imaging and newly launched space tourism and exploration businesses, World View is working to ensure its ultimate objective: honor the planet so that future generations will feel blessed to call it home. For more information, visit worldview.space .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye